Calculated precursor frequenciesa of peptide-specific CD8+ cells in PBMC on day 1 (peptide-specific/10e6 CD8+ cells)
g209b | g209-2M | Flu | Daysc | |||||
---|---|---|---|---|---|---|---|---|
Pre | Post | Pre | Post | Pre | Post | |||
Peptide aloned | P1 | 356 | 2,109 | 638 | 9,664 | 357 | 2,254 | 41 |
P2 | 667 | 2,863 | 2,218 | 4,916 | 2,177 | 3,064 | 41 | |
P3 | 2,083 | 3,451 | 1,558 | 4,301 | 1,115 | 1,274 | 223 | |
P4 | 1,854 | 14,806 | 2,587 | 23,952 | 2,870 | 1e | 43 | |
P5 | 104 | 4,402 | 1,416 | 3,440 | 4,732 | 5,703 | 46 | |
P6 | 4,779 | 9,137 | 5,473 | 12,723 | 6,820 | 7,901 | 94 | |
P7 | 454 | 1,988 | 408 | 1,564 | 415 | 2,389 | 41 | |
Peptide+ IL-12 | P8 | 508 | 4,177 | 500 | 5,609 | 2,002 | 1,237 | 42 |
P9 | 497 | 2,199 | 401 | 1,714 | 480 | 667 | 90 | |
P10 | 282 | 3,135 | 243 | 3,488 | 836 | 1,386 | 40 | |
P11 | 8,566 | 6,834 | 12,490 | 13,618 | 2,054 | 4,164 | 42 | |
P12 | 4,770 | 14,549 | 2,274 | 24,576 | 21,583 | 16,650 | 42 | |
Peptide+ IL-2 | P13 | 2,141 | 121 | 1,735 | 853 | 1,992 | 1 | 283 |
P14 | 1,895 | 1,714 | 1,607 | 2,335 | 663 | 1,026 | 199 | |
P15 | 1,842 | 9,524 | 1,791 | 10,043 | 1,519 | 4,941 | 89 | |
P16 | 7,225 | 4,887 | 4,620 | 2,771 | 2,228 | 1,473 | 184 | |
P17 | 1 | 433 | 300 | 533 | 14,496 | 6,309 | 45 | |
P18 | 2,345 | 971 | 1,755 | 272 | 421 | 1 | 145 | |
P19 | 616 | 271 | 1,051 | 251 | 1,690 | 1,656 | 54 | |
P20 | 2,558 | 950 | 769 | 979 | 908 | 2,687 | 50 | |
P21 | 1,870 | 239 | 895 | 306 | 838 | 260 | 94 | |
P22 | 3,134 | 1,813 | 4,507 | 1,338 | 1,838 | 1,341 | 41 | |
P23 | 2,427 | 1,057 | 2,426 | 869 | 1,374 | 465 | 85 |
a Frequency calculation: [URQ/(LRQ + URQ) × 10e6]epitope-specific − [URQ/(LRQ + URQ) × 10e6]background.
b Staining with g209-, g209-2M-, or Flu-tHLA.
c Time interval between the pre- and postvaccination sample.
d Treatment group.
e Calculated frequencies below or equal to zero were arbitrarily set to 1 to permit statistical analysis involving log10.